OTC Markets OTCPK - Delayed Quote USD

Relief Therapeutics Holding SA (RLFTY)

1.4200 +0.0550 (+4.03%)
At close: May 16 at 3:51 PM EDT
Currency in CHF All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
6,033.0000
6,033.0000
6,081.0000
3,321.0000
--
--
Cost of Revenue
1,736.0000
1,736.0000
1,250.0000
19,774.0000
13,672.0000
--
Gross Profit
4,297.0000
4,297.0000
4,831.0000
-16,453.0000
-13,672.0000
--
Operating Expense
24,075.0000
24,075.0000
40,305.0000
18,158.0000
6,821.0000
--
Operating Income
-19,778.0000
-19,778.0000
-35,474.0000
-34,611.0000
-20,493.0000
--
Net Non Operating Interest Income Expense
-791.0000
-791.0000
-1,902.0000
-1,276.0000
-162.0000
--
Other Income Expense
-91,115.0000
-91,115.0000
-16,940.0000
362.0000
14,394.0000
--
Pretax Income
-111,684.0000
-111,684.0000
-54,316.0000
-35,525.0000
-6,261.0000
--
Tax Provision
-13,503.0000
-13,503.0000
-3,526.0000
-820.0000
1,567.0000
--
Net Income Common Stockholders
-98,181.0000
-98,181.0000
-50,790.0000
-34,705.0000
-7,828.0000
--
Diluted NI Available to Com Stockholders
-98,181.0000
-98,181.0000
-50,790.0000
-34,705.0000
-7,828.0000
--
Basic EPS
-7.35
-8.35
-4.80
-4.00
-1.20
--
Diluted EPS
-7.35
-8.35
-4.80
-4.00
-1.20
--
Basic Average Shares
10,916.9100
11,752.4660
10,570.2810
8,982.6730
6,033.0570
--
Diluted Average Shares
10,916.9100
11,752.4660
10,570.2810
8,982.6730
6,033.0570
--
Total Operating Income as Reported
-110,828.0000
-110,828.0000
-52,040.0000
-34,306.0000
-9,085.0000
--
Total Expenses
25,811.0000
25,811.0000
41,555.0000
37,932.0000
20,493.0000
--
Net Income from Continuing & Discontinued Operation
-98,181.0000
-98,181.0000
-50,790.0000
-34,705.0000
-7,828.0000
--
Normalized Income
-17,983.6746
-17,983.6746
-34,630.8206
-35,040.0828
-20,079.1176
--
Interest Income
93.0000
93.0000
18.0000
40.0000
7.0000
--
Interest Expense
330.0000
330.0000
1,434.0000
797.0000
100.0000
--
Net Interest Income
-791.0000
-791.0000
-1,902.0000
-1,276.0000
-162.0000
--
EBIT
-111,354.0000
-111,354.0000
-52,882.0000
-34,728.0000
-6,161.0000
--
EBITDA
-108,036.0000
-108,036.0000
-49,022.0000
-32,692.0000
-6,161.0000
--
Reconciled Cost of Revenue
1,736.0000
1,736.0000
1,250.0000
19,774.0000
13,672.0000
--
Reconciled Depreciation
3,318.0000
3,318.0000
3,860.0000
2,036.0000
--
--
Net Income from Continuing Operation Net Minority Interest
-98,181.0000
-98,181.0000
-50,790.0000
-34,705.0000
-7,828.0000
--
Total Unusual Items Excluding Goodwill
-91,227.0000
-91,227.0000
-17,281.0000
343.0000
14,386.0000
--
Total Unusual Items
-91,227.0000
-91,227.0000
-17,281.0000
343.0000
14,386.0000
--
Normalized EBITDA
-16,809.0000
-16,809.0000
-31,741.0000
-33,035.0000
-20,547.0000
--
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0000
0.0001
--
Tax Effect of Unusual Items
-11,029.6746
-11,029.6746
-1,121.8206
7.9172
2,134.8824
--
12/31/2019 - 11/23/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

HALB Halberd Corporation
0.0082
-3.53%
 
RGBP Regen BioPharma, Inc.
0.9688
+2.67%
 
TRAW Traws Pharma, Inc.
0.6500
+7.05%
 
PHAR Pharming Group N.V.
8.44
-4.63%
 
SVRA Savara Inc.
3.9600
-1.49%
 
AEZS Aeterna Zentaris Inc.
7.34
+1.12%
 
BCLI Brainstorm Cell Therapeutics Inc.
0.4111
-0.48%
 
ALNY Alnylam Pharmaceuticals, Inc.
152.78
+2.33%
 
NRXP NRx Pharmaceuticals, Inc.
3.2100
-5.59%
 
ALLO Allogene Therapeutics, Inc.
2.3200
-3.73%